* Adaptimmune receives access to priority medicines (PRIME)
regulatory support for its Spear T-cell therapy targeting NY-ESO
for treatment of soft tissue sarcoma
Source text for Eikon:
Further…
The post BRIEF-Adaptimmune gets priority medicines regulatory support for its Spear T-cell therapy appeared first on NASDAQ.